Altimmune (0A4C) Price & Analysis

0 Followers

0A4C Stock Chart & Stats

$2.89

$0.00(0.00%)

At close: Jul 29 4:00 PM EDT

$2.89

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$2.89 - $5.87

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

$552.31M

Enterprise Value$87.61

Total Cash (Recent Filing)$331.54M

Total Debt (Recent Filing)$35.85M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Aug 06, 2026

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.93

Shares Outstanding194,474,150

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)1.41

Price to Sales (P/S)7757.46

P/FCF Ratio-4.71

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$15.25

Price Target Upside427.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.6

Revenue Forecast (FY)$1.88K

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet & Pro Forma Cash RunwayA debt-free balance sheet and ~$535M pro forma cash materially increase Altimmune’s ability to fund global Phase III start‑up and multi-year trials without immediate dilutive financing. This financial flexibility supports longer-term execution, CRO commitments, and clinical supply obligations through registrational milestones.

Regulatory Recognition — Breakthrough TherapyBreakthrough Therapy designation and alignment with FDA/EMA on PERFORMA protocol de‑risks regulatory pathway, enables more frequent regulator engagement, and can accelerate review timelines. This structural recognition raises the program’s probability of efficient development and potential expedited access if trials confirm benefit.

Positive Phase II Signals Across IndicationsRobust Phase II efficacy and tolerability in RECLAIM (AUD) plus prior IMPACT MASH signals strengthen pemvidutide’s value proposition across metabolic and liver indications. Consistent biomarker and clinical endpoints improve confidence in translatability to registrational studies and increase partnership and label expansion optionality.

Bears Say

Persistent Cash Burn And Weak Cash GenerationOngoing negative operating and free cash flow create structural reliance on capital markets or partnerships until commercial revenue emerges. Despite pro forma proceeds, sustained development costs for multi‑year Phase III programs mean dilution or new funding rounds remain likely if timelines extend or additional programs are pursued.

Long Phase III Timelines To Registrational ReadoutA 52‑week biopsy primary endpoint and a multi‑year global Phase III create an extended horizon to potential approval and revenue, raising execution risk and capital consumption over time. Long timelines magnify the impact of operational setbacks and allow competitors more opportunity to capture market share before launch.

Intense Competitive LandscapeA crowded GLP‑1/dual‑ and triple‑agonist field heightens the need for clear clinical differentiation on tolerability and liver efficacy. Competitive entrants with established brands or broader efficacy could limit market share and pricing power, requiring stronger post‑approval evidence or strategic partnerships to secure commercial success.

Altimmune News

Altimmune initiates PERFORMA trial

Altimmune (ALT) announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the...

2d ago

ALT

Barclays says trial data highlights meaningful opportunity for Altimmune in AUD

Barclays analyst Eliana Merle notes Altimmune (ALT) reported topline data from the Phase 2 RECLAIM trial of pemvidutide...

7d ago

ALT

H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune

H.C. Wainwright reiterates a Buy rating on Altimmune (ALT) with a $20 price target saying the company announced...

7d ago

ALT

Leerink remains bullish on Altimmune following ‘positive’ AUD trial results

Leerink notes Altimmune (ALT) announced “positive topline results” from its Phase 2 RECLAIM trial of lead asset pemvidutide...

7d ago

ALT

Unusually active option classes on open July 28th

Unusual total active option classes on open include: Hubbell (HUBB), Kimberly Clark (KMB), Altimmune (ALT), Replimune Group (REPL),...

7d ago

ALT

HTZ

Altimmune announces RECLAIM trial met primary endpoint

Altimmune (ALT) announced topline results from the RECLAIM Phase 2 trial evaluating pemvidutide, an investigational balanced glucagon/GLP-1 dual...

8d ago

ALT

ALT Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Altimmune (ALT) is scheduled to report 2nd quarter earnings on 08/06/2026. Regarding Q2 estimates, Wall Street analysts expect...

16h ago

ALT

Altimmune’s RECLAIM Study Adds an Addiction Angle to Its Obesity Drug

Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune’s RECLAIM study looks at whether its drug...

4d ago

ALT

Altimmune Reports Positive Phase 2 Data in AUD

Altimmune ( ($ALT) ) just unveiled an announcement. On July 28, 2026, Altimmune reported positive topline data from...

8d ago

ALT

BWXT, Altimmune, Global Payments, AbbVie, Nike Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($BWXT) ), ( ($ALT) ), ( ($GPN) ), ( ($ABBV)...

1M ago

ALT

GPN

Unusually active option classes on open June 24th

Unusual total active option classes on open include: iShares Germany (EWG), Sunrun (RUN), Altimmune (ALT), Newell Brands (NWL),...

1M ago

ALT

Altimmune initiated with an Outperform at Leerink

Leerink analyst Thomas Smith initiated coverage of Altimmune (ALT) with an Outperform rating and $10 price target Altimunne...

1M ago

ALT

Altimmune initiated with an Outperform at Leerink

Leerink initiated coverage of Altimmune (ALT) with an Outperform rating and $10 price target Published first on TheFly...

1M ago

ALT

Altimmune Relocates Corporate Headquarters to Morristown, New Jersey

The latest announcement is out from Altimmune ( ($ALT) ). On June 16, 2026, Altimmune, Inc. announced it...

2M ago

ALT

0A4C FAQ

What was Altimmune Inc’s price range in the past 12 months?

Altimmune Inc lowest share price was $2.89 and its highest was $5.87 in the past 12 months.

What is Altimmune Inc’s market cap?

Altimmune Inc’s market cap is $552.31M.

When is Altimmune Inc’s upcoming earnings report date?

Altimmune Inc’s upcoming earnings report date is Aug 06, 2026 which is tomorrow.

How were Altimmune Inc’s earnings last quarter?

Altimmune Inc released its earnings results on May 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.

Is Altimmune Inc overvalued?

According to Wall Street analysts Altimmune Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Altimmune Inc pay dividends?

Altimmune Inc does not currently pay dividends.

What is Altimmune Inc’s EPS estimate?

Altimmune Inc’s EPS estimate is -0.14.

How many shares outstanding does Altimmune Inc have?

Altimmune Inc has 194,474,150 shares outstanding.

What happened to Altimmune Inc’s price movement after its last earnings report?

Altimmune Inc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Altimmune Inc?

Currently, no hedge funds are holding shares in GB:0A4C

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Altimmune Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

113.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Altimmune Inc

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Altimmune (0A4C) Earnings & Revenues

Historic Earnings Reports

0A4C Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed significant progress: strong financing ($225M offering; $535M pro forma cash), regulatory recognition (Breakthrough Therapy), alignment with FDA/EMA on the PERFORMA Phase III protocol, robust Phase II efficacy/tolerability signals, and near-term readouts (AUD topline; RESTORE enrollment). Challenges were mostly operational and expected for a late-stage biotech: higher G&A and R&D as programs advance, a wider net loss in the quarter, ongoing validation/integration of digital pathology tools, and a competitive landscape necessitating clear differentiation. Overall, the positives — especially the cash runway and Phase III readiness — materially outweigh the manageable execution and competitive risks.View all GB:0A4C earnings summaries

0A4C Stock 12 Month Forecast

Average Price Target

$15.25

▲(427.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.889,4.205230769230769,5.521461538461539,6.837692307692308,8.153923076923077,9.470153846153845,10.786384615384616,12.102615384615385,13.418846153846154,14.735076923076923,16.05130769230769,17.367538461538462,18.683769230769233,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.889,3.8398461538461537,4.790692307692307,5.741538461538461,6.692384615384615,7.643230769230769,8.594076923076923,9.544923076923077,10.49576923076923,11.446615384615384,12.397461538461538,13.348307692307692,14.299153846153846,{"y":15.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.889,3.436,3.9829999999999997,4.529999999999999,5.077,5.6240000000000006,6.170999999999999,6.718,7.265000000000001,7.811999999999999,8.359,8.906,9.453,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.683,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.683,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.683,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.865,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 54, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.889,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 90, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >